- 5/19/2009 - VasoGenix Pharmaceuticals elects Cleveland Clinic’s James Young, M.D., to its board of directors
LENEXA, Kan., May 19, 2009—VasoGenix Pharmaceuticals announced today that heart failure/heart transplant cardiologist James Young, M.D., has been elected to its board of directors.
- 3/23/2009 - VasoGenix Pharmaceuticals Elects Pharma Industry Veteran Dr. Judith A. Hemberger to Its Board of Dir
LENEXA, Kan.--(BUSINESS WIRE)-- VasoGenix Pharmaceuticals announced today that Judith A. Hemberger, Ph.D., has been elected to its board of directors. Dr. Hemberger is currently a director of Zymogenetics, Chroma, Atani Ltd., and Zosano Pharma.
- 2/11/2009 - VasoGenix Selects a Lead CGRP Agonist Analog to Develop as a Heart Failure Treatment
LENEXA, Kan., Feb 11, 2009 (BUSINESS WIRE) -- VasoGenix Pharmaceuticals Inc. (www.vasogenix.net) announced today that initial in vitro screening of a series of synthetic agonist analogs of calcitonin gene-related peptide (CGRP) exhibit similar receptor site binding properties as CGRP.
- 2/4/2009 - VasoGenix Pharmaceuticals Elects Former Avax Technologies CEO Richard P. Rainey to Its Board of Dire
LENEXA, Kan.--(BUSINESS WIRE)--VasoGenix Pharmaceuticals announced today that Richard P. Rainey, CPA, former CEO of Avax Technologies, a publicly traded biotechnology company, has been elected to its board of directors.
- 1/29/2009 - VasoGenix Pharmaceuticals awarded $400K from Kansas Bioscience Authority
Lenexa-based VasoGenix Pharmaceuticals Inc. received an investment of $400,000 from the Kansas Bioscience Authority’s latest round of financing to help support development of an intravenous and controlled-release drug treatment for heart failure. The company is raising capital to file an investigational new drug application with the Food and Drug Administration.
- 12/23/2008 - VasoGenix to present at the 2009 Biotech Showcase
The Biotech Showcase will be held in San Francisco, California at the Marines' Memorial Club & Hotel, Wednesday, January 14th at 2:30 PM in Room A
- 10/27/2008 - Analogs of CGRP May Be Useful in Treating Heart Failure
LENEXA, Kan., Oct 27, 2008 (BUSINESS WIRE) -- VasoGenix Pharmaceuticals Inc. announced today that preclinical in vivo screening of a series of synthetic analogs of calcitonin gene-related peptide ('CGRP'), which naturally occurs in humans, retained the properties of CGRP at equal or greater potency.
- 9/30/2008 - VasoGenix presenting at MidAmerica Healthcare Forum
VasoGenix has been selected to present at the Midwest’s largest annual event showcasing biotech, pharma, medical devices, and industrial biotech companies in the heartland of America.
Location: Westin Cincinnati; Wednesday October 1, 2008; 2:00-3:00 TRACK 3 Biotechnology & Pharmaceutical Company Showcase.
www.midamericahealthcareforum.com.
- 7/18/2008 - VasoGenix receives $400,000 capital infusion.
Kansas City Business Journal
Friday, July 18, 2008. Kansas Bioscience Authority and Capital Midwest Fund make investments in VasoGenix Pharmaceuticals.
- 3/14/2008 - VasoGenix engages Einhorn Associates as financial advisor.
For inquiries or requests for additional information on VasoGenix contact Einhorn Associates at 414-453-4488.
- 11/6/2007 - VasoGenix sponsored research presented at AHA Scientific Sessions
Abstract 772: Calcitonin-gene Related Peptide Receptor Regulation In Human Heart Failure
- 6/21/2006 - VasoGenix Pharmaceuticals to Present at Conference
VasoGenix Pharmaceuticals to Present at Medtech Insight and Windhover
Informations
- 6/13/2006 - Halperin elected to Board of Directors
Jerome A. Halperin elected to the Company's Board of Directors
- 5/16/2006 - VasoGenix, Cleveland Clinic to study CGRP
VasoGenix has entered into an agreement with Cleveland Clinic to research the application of CGRP
- 5/15/2006 - VasoGenix and Cleveland Clinic to develop CGRP
VasoGenix Pharmaceuticals and Cleveland Clinic sign Phase I/II safety and
efficacy clinical trial agreement
- 11/2/2005 - Wall Street Reporter Article- All Eyes Upon the Perfect Cardiology Drug
Issue No. 105B 2005 Wall Street Reporter
- 11/1/2005 - Genomics & Proteomics- Biotech Breeding Grounds
Investment capital and proximity to talent are key ingredients to raise a herd of world-class biotechs. In the race for the next biotech hub, developed countries don't always have all the advantages. Nov/Dec 2005 Issue GenPro Magazine
- 6/1/2005 - Windhovers Review of Emerging Medical Ventures
Comprehensive cardioprotection for myocardial infarction.